Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:50 p.m.

    📋 BEIGENE, LTD. (BGNE) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 07:08:06

    Event Type: Financial Results

    Event Details:

    BeiGene Ltd (BGNE) Reports Q3 2022 Financial Results BeiGene Ltd (BGNE) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 71173
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 5707963
      • year basis,” said John V. Oyler, Co
      • Founder, Chairman and Chief Executive Officer of BeiGene. “We continue to unlock opportunity driven by our research and development engine and, during the second half of this year, expect to share final analysis data for our global Phase 3 ALPINE trial of BRUKINSA, including progression
      • free survival in chronic lymphocytic leukemia as well as topline data for tislelizumab as a first
        • targeting the LAG-3 pathway, in combination with tislelizumab and surzebiclimab (TIM3) in 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Assets Property Equipment Net 633.10K 587.61K $45.49K +7.74%
    Liabilities And Equity Accounts Payable 234.35K 262.40K $-28.05K -10.69%
    Expenses Selling General Administrative 232.29K 625.98K $-393.69K -62.89%
    Expenses Loss From Operations -474.84K -882.69K $407.85K +46.21%
    Expenses Net Loss -480.34K -1.01M $525.38K +52.24%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BeiGene Ltd
    • CIK: 0001651308
    • Ticker Symbol: BGNE
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories